Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BGMS NASDAQ:ELAB NASDAQ:ENVB NASDAQ:MBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBGMSCyclacel Pharmaceuticals$0.89-1.0%$0.93$0.57▼$19.87$4.92M-0.381.11 million shs5,137 shsELABPMGC$1.05-2.0%$1.47$1.00▼$309.12$1.21M-0.234.72 million shs80,195 shsENVBEnveric Biosciences$1.29+1.2%$1.71$1.26▼$17.64$4.73M1.151.95 million shs3,007 shsMBIOMustang Bio$0.62-4.9%$0.68$0.53▼$2.12$4.70M2.05141,035 shs2,884 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBGMSCyclacel Pharmaceuticals-5.05%-0.84%+18.72%-23.73%+89,999,900.00%ELABPMGC0.00%-1.83%-23.02%-67.48%-99.46%ENVBEnveric Biosciences-5.22%-3.05%-0.78%-62.31%-91.98%MBIOMustang Bio+3.79%-1.78%+0.31%-8.95%-70.09%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBGMSCyclacel Pharmaceuticals$0.89-1.0%$0.93$0.57▼$19.87$4.92M-0.381.11 million shs5,137 shsELABPMGC$1.05-2.0%$1.47$1.00▼$309.12$1.21M-0.234.72 million shs80,195 shsENVBEnveric Biosciences$1.29+1.2%$1.71$1.26▼$17.64$4.73M1.151.95 million shs3,007 shsMBIOMustang Bio$0.62-4.9%$0.68$0.53▼$2.12$4.70M2.05141,035 shs2,884 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBGMSCyclacel Pharmaceuticals-5.05%-0.84%+18.72%-23.73%+89,999,900.00%ELABPMGC0.00%-1.83%-23.02%-67.48%-99.46%ENVBEnveric Biosciences-5.22%-3.05%-0.78%-62.31%-91.98%MBIOMustang Bio+3.79%-1.78%+0.31%-8.95%-70.09%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBGMSCyclacel Pharmaceuticals 1.00SellN/AN/AELABPMGC 1.00SellN/AN/AENVBEnveric Biosciences 1.00SellN/AN/AMBIOMustang Bio 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest ELAB, BGMS, ENVB, and MBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026ENVBEnveric Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/17/2026MBIOMustang Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/14/2026BGMSCyclacel Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)6/26/2026ELABPMGC Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/24/2026BGMSCyclacel Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026ENVBEnveric Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026MBIOMustang Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 7/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBGMSCyclacel Pharmaceuticals$750K6.56N/AN/A$1.40 per share0.64ELABPMGC$590K2.06N/AN/A$93.33 per share0.01ENVBEnveric BiosciencesN/AN/AN/AN/A$7.00 per shareN/AMBIOMustang BioN/AN/AN/AN/A$1.31 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBGMSCyclacel Pharmaceuticals-$3M-$4.54N/AN/AN/AN/A-51.21%-44.00%N/AELABPMGC-$7.75M-$168.62N/AN/AN/AN/A-117.82%-70.79%N/AENVBEnveric Biosciences-$8.77M-$23.54N/AN/AN/AN/A-220.97%-177.47%8/17/2026 (Estimated)MBIOMustang Bio-$1.92M-$0.48N/AN/AN/AN/A-35.38%-16.36%8/18/2026 (Estimated)Latest ELAB, BGMS, ENVB, and MBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/18/2026Q2 2026MBIOMustang Bio-$145.50N/AN/AN/AN/AN/A5/15/2026Q1 2026ENVBEnveric BiosciencesN/A-$1.08N/A-$1.08N/AN/A5/14/2026Q1 2026BGMSCyclacel PharmaceuticalsN/A-$0.04N/A-$0.04N/A$0.78 million5/14/2026Q1 2026ELABPMGCN/A-$11.2190N/A-$11.2190N/A$0.68 million5/5/2026Q1 2026MBIOMustang Bio-$140.00-$0.14+$139.86-$0.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBGMSCyclacel PharmaceuticalsN/AN/AN/AN/AN/AELABPMGCN/AN/AN/AN/AN/AENVBEnveric BiosciencesN/AN/AN/AN/AN/AMBIOMustang BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBGMSCyclacel PharmaceuticalsN/A7.065.87ELABPMGC0.031.451.43ENVBEnveric BiosciencesN/A11.6611.66MBIOMustang BioN/A2.122.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBGMSCyclacel Pharmaceuticals23.58%ELABPMGC22.22%ENVBEnveric Biosciences13.82%MBIOMustang Bio9.95%Insider OwnershipCompanyInsider OwnershipBGMSCyclacel Pharmaceuticals23.75%ELABPMGC0.01%ENVBEnveric Biosciences2.41%MBIOMustang Bio4.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBGMSCyclacel Pharmaceuticals145.52 million4.21 millionN/AELABPMGC181.16 million1.16 millionN/AENVBEnveric Biosciences203.68 million3.59 millionNot OptionableMBIOMustang Bio1007.58 million7.27 millionNot OptionableELAB, BGMS, ENVB, and MBIO HeadlinesRecent News About These CompaniesMindBio Completes Manufacture and Delivery of First Prototype Edge AI Intoxication and Fatigue Detection KiosksJune 9, 2026 | globenewswire.comMindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Harnesses Key AI, Voice Analysis to Offer Impairment SolutionMay 14, 2026 | globenewswire.comIBN Announces Latest Episode of The TechMediaWire Podcast featuring Justin Hanka, CEO of MindBio Therapeutics Corp.May 12, 2026 | globenewswire.comMindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Leveraging AI, Voice Analysis to Develop Intoxication DetectionMay 12, 2026 | globenewswire.comMindBio Announces Closing of Private PlacementApril 1, 2026 | thenewswire.comTMindBio Announces Private Placement to Raise up to $650,000February 18, 2026 | thenewswire.comTMustang Bio Inc.July 25, 2025 | barrons.comTalisker Receives Assay Results from 1105 Level Lateral Development at the Mustang MineJuly 24, 2025 | globenewswire.comMBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy - NasdaqJuly 10, 2025 | nasdaq.comMustang Bio Stock Jumps 180% After FDA Grants Orphan Drug Status to Brain Cancer DrugJuly 10, 2025 | msn.comBiotech Stock Mustang Bio, Inc. (Nasdaq: MBIO) Soars on Orphan Drug Designation by U.S. FDAJuly 9, 2025 | investorideas.comIMustang Bio Inc News (MBIO) - Investing.comJuly 9, 2025 | investing.comMBIO Soars on Orphan Drug Nod for Investigational Brain Cancer TherapyJuly 8, 2025 | zacks.comDow Dips 1%; Mustang Bio Shares Spike HigherJuly 7, 2025 | benzinga.comThis BlackRock stock just spiked over 300%July 7, 2025 | finbold.comFMustang Bio stock soars after FDA grants orphan drug designationJuly 7, 2025 | investing.comMustang Bio rises after FDA orphan drug status for MB-101July 7, 2025 | msn.comMustang Bio Shares Surge After FDA Grants Orphan Drug StatusJuly 7, 2025 | msn.comMustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and GlioblastomaJuly 7, 2025 | globenewswire.comMustang Bio, Inc. (MBIO) - Yahoo FinanceJuly 2, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeELAB, BGMS, ENVB, and MBIO Company DescriptionsCyclacel Pharmaceuticals NASDAQ:BGMS$0.89 -0.01 (-1.00%) As of 10:15 AM Eastern This is a fair market value price provided by Massive. Learn more.Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.PMGC NASDAQ:ELAB$1.05 -0.02 (-1.96%) As of 10:20 AM Eastern This is a fair market value price provided by Massive. Learn more.Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.Enveric Biosciences NASDAQ:ENVB$1.28 +0.02 (+1.18%) As of 10:18 AM Eastern This is a fair market value price provided by Massive. Learn more.Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.Mustang Bio NASDAQ:MBIO$0.62 -0.03 (-4.86%) As of 09:43 AM EasternMustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Buy, Hold, or Wait: 3 Small-Cap Stocks Telling Different Stories The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino's Stock Serving Up a Buying Opportunity? IBM Just Had Its Worst Day Ever—What Earnings Must Prove AI Data Centers Need Power, and These 2 Industrials Are Cashing In 5 Stocks Quietly Trading Near All-Time Highs While Everyone Watches the AI Drama Meta Platforms Turns AI Power Scarcity Into a $10 Billion Cloud Bet Oracle Is One Step From Junk—Can It Afford the AI Boom? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
